Literature DB >> 10047624

Prognostic significance of double product and inadequate double product response to maximal symptom-limited exercise stress testing after myocardial infarction in 6296 patients treated with thrombolytic agents. GISSI-2 Investigators. Grupo Italiano per lo Studio della Sopravvivenza nell-Infarto Miocardico.

M Villella1, A Villella, S Barlera, M G Franzosi, A P Maggioni.   

Abstract

BACKGROUND: The aim of this study was to evaluate the prognostic significance of the pressure-rate product (PRP) obtained during exercise stress testing and of its change from rest to maximal exercise (dPRP) in a population of survivors of acute myocardial infarction treated with thrombolytic agents. METHODS AND
RESULTS: Survivors of acute myocardial infarction (n = 6251) from the GISSI-2 database, who underwent a maximal symptom-limited exercise test with either bicycle ergometer or treadmill, were followed up for 6 months. PRP and dPRP values were dichotomized (</=21,700 and >21,700, </=11, 600 and >11,600, respectively) and analyzed in a multivariate Cox model individually and simultaneously with other ergometric variables. Six-month mortality rate was 0.8% in the high PRP group and 2.0% in the low PRP group. Low PRP was an independent predictor of 6-month mortality rate (relative risk [RR] 1.97, 95% confidence interval [CI] 1.24 to 3.13). Patients with low dPRP had mortality rates higher than patients with high dPRP (2.1% vs 0.8%). At the multivariate analysis, low dPRP showed negative predictive value (RR 1.97, 95% CI 1.23 to 3.16). A further multivariate analysis was performed with PRP and dPRP, also adjusting for low work capacity, abnormal systolic blood pressure response to exercise, and symptomatic-induced ischemia. The results showed that low work capacity, low PRP, and symptomatic exercise-induced ischemia were still significantly associated with higher 6-month mortality rate (P =.04,.02, and.05; RR = 1.68, 1.71, and 1.78 respectively).
CONCLUSIONS: PRP is a predictive index to assess prognosis in survivors of acute myocardial infarction treated with thrombolytic agents able to perform an exercise test after acute myocardial infarction, but its usefulness appears to be limited, considering that these patients were at low risk.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10047624     DOI: 10.1016/s0002-8703(99)70490-4

Source DB:  PubMed          Journal:  Am Heart J        ISSN: 0002-8703            Impact factor:   4.749


  14 in total

1.  Relationship Between Birth Weight and the Double Product in Childhood, Adolescence, and Adulthood (from the Bogalusa Heart Study).

Authors:  Fu Wang; Yingxiao Hua; Paul K Whelton; Tao Zhang; Camilo Alonso Fernandez; Huijie Zhang; Lydia Bazzano; Jiang He; Wei Chen; Shengxu Li
Journal:  Am J Cardiol       Date:  2017-06-28       Impact factor: 2.778

2.  Is downstream cardiac testing required in patients with reduced functional capacity and otherwise negative exercise stress test? A single center observational study.

Authors:  Mark Whitman; Surendran Sabapathy; Carly Jenkins; Lewis Adams
Journal:  Cardiol J       Date:  2018-09-20       Impact factor: 2.737

3.  Prognostic value of daytime heart rate, blood pressure, their products and quotients in chronic heart failure.

Authors:  Anna Kowalczys; Michał Bohdan; Marcin Gruchała
Journal:  Cardiol J       Date:  2017-11-13       Impact factor: 2.737

4.  Rate-pressure product-derived global coronary flow reserve (CFR): an unrecognized parameter available during all standard exercise ECG stress tests and conventional exercise SPECT myocardial perfusion studies (exMPS).

Authors:  Victor Kalff; Stephen J Duffy; Philipp A Kaufmann
Journal:  J Nucl Cardiol       Date:  2014-01-16       Impact factor: 5.952

5.  Use of atropine in patients with recent myocardial infarction during exercise myocardial perfusion study. Use of atropine during exercise myocardial perfusion SPECT.

Authors:  S Barai; C D Patel; A Malhotra; G P Bandopadhayaya; S Gambhir; R Kumar; H Dhanapathi
Journal:  Int J Cardiovasc Imaging       Date:  2005-08       Impact factor: 2.357

6.  Long-term effects of smoking and smoking cessation on exercise stress testing: three-year outcomes from a randomized clinical trial.

Authors:  Asha Asthana; Megan E Piper; Patrick E McBride; Ann Ward; Michael C Fiore; Timothy B Baker; James H Stein
Journal:  Am Heart J       Date:  2011-11-14       Impact factor: 4.749

7.  Circadian variation in the circulatory responses to exercise: relevance to the morning peaks in strokes and cardiac events.

Authors:  Greg Atkinson; Helen Jones; Philip N Ainslie
Journal:  Eur J Appl Physiol       Date:  2009-10-14       Impact factor: 3.078

8.  Double product reflects the predictive power of systolic pressure in the general population: evidence from 9,937 participants.

Authors:  Rudolph Schutte; Lutgarde Thijs; Kei Asayama; José Boggia; Yan Li; Tine W Hansen; Yan-Ping Liu; Masahiro Kikuya; Kristina Björklund-Bodegård; Takayoshi Ohkubo; Jørgen Jeppesen; Christian Torp-Pedersen; Eamon Dolan; Tatiana Kuznetsova; Katarzyna Stolarz-Skrzypek; Valérie Tikhonoff; Sofia Malyutina; Edoardo Casiglia; Yuri Nikitin; Lars Lind; Edgardo Sandoya; Kalina Kawecka-Jaszcz; Jan Filipovsky; Yutaka Imai; Jiguang Wang; Hans Ibsen; Eoin O'Brien; Jan A Staessen
Journal:  Am J Hypertens       Date:  2013-02-07       Impact factor: 2.689

9.  The association of clinical indication for exercise stress testing with all-cause mortality: the FIT Project.

Authors:  Joonseok Kim; Mouaz Al-Mallah; Stephen P Juraschek; Clinton Brawner; Steve J Keteyian; Khurram Nasir; Zeina A Dardari; Roger S Blumenthal; Michael J Blaha
Journal:  Arch Med Sci       Date:  2016-04-12       Impact factor: 3.318

10.  South Asians have elevated postexercise blood pressure and myocardial oxygen consumption compared to Europeans despite equivalent resting pressure.

Authors:  Nish Chaturvedi; Rajaram Bathula; Angela C Shore; Ronney Panerai; John Potter; Jaspal Kooner; John Chambers; Alun D Hughes
Journal:  J Am Heart Assoc       Date:  2012-10-25       Impact factor: 5.501

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.